Slide 1: Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines
Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines Vaccine Summit 2025 November 6, 2025 Boston, Massachusetts, USA © 2022 IMUNON Inc. PAGE 1
Slide 2: DNA Vaccines are Well-Suited to Overcome the Limitations of Current mRNA and Protein Vaccines
DNA Vaccines are Well-Suited to Overcome the Limitations of Current mRNA and Protein Vaccines Current Vaccines & their Limitations Advantages of DNA Vaccines mRNA • Longer duration of antigen expression/ • Short duration of antigen expression & exposure immune responses • Strong T-cell responses (co
Slide 3: DNA Vaccines Require a DNA Delivery System
DNA Vaccines Require a DNA Delivery System Current Delivery Systems Warrant Alternate Approaches Viral Vectors • Biological in nature • High delivery efficiency • Poor repeatability • Safety limitations Electroporation devices • User compliance • Tissue damage • Additional cost Jet devices • Injecti
Slide 4: PlaCCine – A Novel DNA Vaccine Platform Technology
PlaCCine – A Novel DNA Vaccine Platform Technology Relies on Synthetic Vectors for DNA Delivery PlaCCine Vaccines do not Require Virus or Device: A PlaCCine Synthetic Delivery Systems: covalently-functionalized amphiphilic polymer X X Backbone X- functional group: same or different • Dispersion • Ge
Slide 5: PlaCCine Immunogenicity Demonstrated Against Various Pathogens in Multiple Species
PlaCCine Immunogenicity Demonstrated Against Various Pathogens in Multiple Species Pathogens Species • SARS CoV-2 (multiple variants) • Mouse • Influenza • Rabbit • Marburg • Monkey • Lassa • Human • Monkeypox © 2022 IMUNON Inc. PAGE 5
Slide 6: Commercial Advantages of PlaCCine over mRNA Vaccines: Stable at 4°C
Commercial Advantages of PlaCCine over mRNA Vaccines Stable at 4oC for at Least 12 Months • Vector: pVac-17 (D614G-Delta) IgG Response • Formulation: PlaCCine 1m 3m 6m 10 5 9m 12m 10 4 Endpoint Titer 10 3 10 2 4⁰C Storage 1 3 6 9 12 10 1 Months 10 0 4C 4C 4C 4C 4C h h h h h es es es es es Fr Fr Fr F
Slide 7: Commercial Advantages of PlaCCine over mRNA Vaccines: Stable at 37°C
Commercial Advantages of PlaCCine over mRNA Vaccines Stable at 37oC for at Least 14 Days Sodium Citrate PBS NS = 0.141 NS = 0.06 Day-7 10 5 10 5 Day-14 10 4 10 4 Endpoint Titer 10 3 10 3 10 2 10 2 10 1 10 1 10 0 10 0 4C 37C 4o C 4C37o C 4o C 37C37o C 4o C 37o C 4o C 37o C Day 7 Day 7 Day 14 Day 14 ©
Slide 8: IMNN-101 - A COVID-19 Vaccine
IMNN-101 - A COVID-19 Vaccine First-in-Human PlaCCine Vaccine IMNN-101 *XBB1.5 Variant PlaCCine delivery system Spike DNA Vaccine Plasmid Delivery System * Variant of Concern (FDA: VRBPAC 2023) Adjuvant Alum PO4 © 2022 IMUNON Inc. PAGE 8
Slide 9: IMNN-101 - Single Dose, Placebo Controlled Phase 1 Trial in Healthy Subjects
IMNN-101 - Single Dose, Placebo Controlled Phase 1 Trial in Healthy Subjects NCT06283459 Rapid Dose Escalation for Speedy Completion DNA Dose Escalation (mg) 0.5 1.0 2.0 Placebo (n = 8 each) Vaccine -30 Days Day-1 Day-7 Day-28 Day-90 Day-180 Prescreening/ Daily reactogenicity Enrollment assessment f
Slide 10: Demographic Characteristics of the Study Patients
Demographic Characteristics of the Study Patients Baseline All Participants Dose Group 1 Dose Group 2 Dose Group 3 Characteristics (n = 24) (n = 8) (n = 8) (n = 8) Age (years) Mean 47.7 47.9 44.7 50.5 Sex Male 9 (37.5%) 3 (37.5%) 4 (50%) 2 (25%) Female 15 (62.5%) 5 (62.5%) 4 (50%) 6 (75%) Ethnicity
Slide 11: Safety Profile of IMNN-101
Safety Profile of IMNN-101 Treatment-emergent Adverse Events During 6 Month Follow Up n (%) Body System/Class TEAE Preferred Term Grade 1 Grade 2 Grades 3 – 5 (n = 24) Ear and labyrinth Vertigo 1 (4.2%) 1 (4.2%) 0 (0%) 0 (0%) disorders Bronchitis 1 (4.2%) 0 (0%) 1 (4.2%) 0 (0%) Infections and COVID-
Slide 12: NAb Responses to XBB.1.5/JN.1 Variant following a Single Dose of IMNN-101
NAb Responses to XBB.1.5/JN.1 Variant following a Single Dose of IMNN-101 Subjects Previously Infected/Vaccinated Multiple Times XBB.1.5 JN.1 XBB1.5 JN.1 ✱ ns 10 6 week-0 ✱✱ ✱ week-2 10 5 ✱ ✱ week week00 week-4 week week22 IC50 Titer week-24 10 4 241 326 616 512 361 744 869 636 week week44 10 3 week
Slide 13: Dose-dependence of the Neutralizing Antibody Responses to XBB.1.5 and JN.1 Variant
Dose-dependence of the Neutralizing Antibody Responses to XBB.1.5 and JN.1 Variant XBB1.5 JN.1 4 XBB1.5 5 JN1 0.5 mg 0.5mg 0.5 mg 0.5mg 11mg mg 4 1mg 1 mg 3 Fold change Fold change 22mg mg 2mg 2 mg 3 2 2 1 1 0 0 wk2 wk24 wk2 wk24 weeks weeks Fold changes in median NAb titers at different vaccine dos
Slide 14: Cellular Immune Responses to XBB.1.5 & JN.1 Following IMNN-101
Cellular Immune Responses to XBB.1.5 & JN.1 Following IMNN-101 Subjects Previously Infected/Vaccinated Multiple Times CD4+ T-cells CD8+ T-cells % Responders IFN-g TNF-a IL-2 IFN-g TNF-a IL-2 XBB1.5 53% 47% 68% 63% 63% 32% JN.1 56% 61% 61% 50% 63% 50% Highest Fold-increase from Baseline & Dose XBB1.5
Slide 15: T-cell Responses to JN.1 Following a Single Dose of IMNN-101
T-cell Responses to JN.1 Following a Single Dose of IMNN-101 Subjects Previously Infected/Vaccinated Multiple Times CD4+ ns ns Prominent Increases in CD4+ T-cells over Time 10 0 ✱ 10 0 10 0 % TNFα+ / CD4+ T Cells % IFN-γ+ / CD4+ T Cells % IL2 / CD4+ T Cells 0.1 10 -1 10 -1 10 -1 10 -2 10 -2 10 -2 0.
Slide 16: PlaCCine Summary
PlaCCine Summary- • A novel platform for prophylactic vaccines that leverages DNA advantages on: • Durability of antigen expression, temperature stability, flexible manufacturing, rapid development • Safety and immunogenicity demonstrated in healthy human subjects after a single injection. • NAb res